India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...
More »SEARCH RESULT
Government blinks, cotton export ban to go today
-The Economic Times The government has decided to lift the ban on cotton exports from Monday, just a week after imposing it, buckling under pressure from farmers, traders and politicians. "Keeping in view the facts, the interests of farmers, industry and trade, a balanced view has been considered by the group of ministers to roll back the ban and a formal order will be made public on Monday by the government," Commerce...
More »Cotton export ban goes-Sujay Mehdudia
Notification today; GoM will work out riders Allies of the ruling United Progressive Alliance have again forced the Manmohan Singh government to take a step back, this time over the ban on cotton exports. The government has now announced that a new notification revoking the ban imposed on March 5 will be issued on Monday, in what is considered a victory for Agriculture Minister Sharad Pawar, who stoutly opposed the decision, along...
More »India defers decision on cotton export ban
-Reuters India will keep a controversial ban on its cotton exports for now after ministers failed to agree its fate on Friday, even after top buyer China had criticised the move, which boosted global prices. Indian exporters, who have some 2.5 million bales outstanding for overseas sales, are left with the limited consolation of shifting a maximum of 500,000 bales that have already been cleared by customs. "The meeting was inconclusive. Further discussion...
More »Novartis vs India: the showdown approaches by Simon Reid-Henry
The Swiss-based pharmaceutical giant Novartis is taking the state of India to court in a case that has, after rumbling about in the lower courts for six years, wound up as a very public litmus test of the legal framework sustaining India’s generic drugs revolution. With the case due before the Supreme Court on 28 March, the fate of millions who depend on affordable Indian medicines may soon hang in the...
More »